Use of Sacubitril/valsartan in patients with cardio toxicity and heart failure due to chemotherapy

BACKGROUND: Cancer therapy-related cardiac dysfunction (CTRCD) is a critical problem with an impact on both oncological and cardiovascular prognosis, especially when it prevents patients from receiving cancer treatment. Standard therapy for heart failure (HF) is recommended for CTRCD, but there is n...

Descripción completa

Detalles Bibliográficos
Autores principales: Gregorietti, Vanesa, Fernandez, Teresa Lopez, Costa, Diego, Chahla, Elías Ortega, Daniele, Andrés J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7643279/
https://www.ncbi.nlm.nih.gov/pubmed/33292750
http://dx.doi.org/10.1186/s40959-020-00078-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7643279/
https://www.ncbi.nlm.nih.gov/pubmed/33292750
http://dx.doi.org/10.1186/s40959-020-00078-4

Ejemplares similares